18:49 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis Mouse studies suggest inhibiting MCP-1 or its receptor CCR2 could help treat arthritis. In a mouse model of anti-collagen antibody-induced arthritis, systemic MCP-1 knockout or a neutralizing antibody against CCR2 decreased disease severity...
19:30 , Jun 15, 2018 |  BC Week In Review  |  Company News

ChemoCentryx, Vifor Fresenius expand CCX140, avocapan deal to include China

ChemoCentryx Inc. (NASDAQ:CCXI) granted Vifor Fresenius Medical Care Renal Pharma Ltd. exclusive rights to commercialize avacopan (CCX168) and CCX140 in China under the second expansion of a 2016 deal. Vifor Fresenius gained exclusive commercialization rights...
20:58 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; lung cancer Mouse studies suggest inhibiting CCR2 in combination with radiotherapy could help treat colon and lung cancers. In mouse models of colon and lung cancers, systemic knockout of CCR2 plus radiation...
19:22 , Nov 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinopathy of prematurity Patient sample and mouse studies suggest inhibiting mast cell degranulation, TPSB2 or MCP-1-CCR2 signaling could help treat retinopathy of prematurity (ROP). In plasma samples from preterm neonatal infants who developed ROP,...
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and...
21:56 , Dec 30, 2016 |  BC Week In Review  |  Company News

ChemoCentryx, Galenica deal

ChemoCentryx and the Vifor Pharma Ltd. subsidiary of Galenica expanded a 2016 deal to include ChemoCentryx candidate CCX140 . ChemoCentryx granted Vifor exclusive, worldwide rights, excluding the U.S. and China, to CCX140 to treat rare...
00:25 , Dec 23, 2016 |  BC Extra  |  Company News

Vifor, ChemoCentryx expand kidney partnership

ChemoCentryx Inc. (NASDAQ:CCXI) and the Vifor Pharma Ltd. subsidiary of Galenica Ltd. (SIX:GALN) said they will expand their kidney disease partnership to include ChemoCentryx candidate CCX140 , an inhibitor of CC chemokine receptor 2 (...
00:22 , Dec 23, 2016 |  BC Extra  |  Company News

Vifor, ChemoCentryx expand kidney partnership

ChemoCentryx Inc. (NASDAQ:CCXI) and the Vifor Pharma Ltd. subsidiary of Galenica Ltd. (SIX:GALN) said they will expand their kidney disease partnership to include ChemoCentryx candidate CCX140, an inhibitor of CC chemokine receptor 2 (CCR2; CD192)....
07:00 , May 16, 2016 |  BC Week In Review  |  Company News

ChemoCentryx, Galenica deal

ChemoCentryx granted Galenica’s Vifor Pharma Ltd. subsidiary exclusive rights to commercialize CCX168 in Europe, Canada, Mexico, Central and South America and South Korea. ChemoCentryx will receive $85 million up front, including $60 million in cash...
00:48 , May 11, 2016 |  BC Extra  |  Company News

ChemoCentryx, Vifor in deal for rare renal disease candidate

ChemoCentryx Inc. (NASDAQ:CCXI) rose $0.89 (42%) to $2.99 on Tuesday after it granted the Vifor Pharma Ltd. subsidiary of Galenica Ltd. (SIX:GALN) exclusive rights to commercialize CCX168 in Europe, Canada, Mexico, Central and South America...